Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 4/20 | 0.56 |
| ▸ | CPB1 | P15086 | 1/20 | 0.56 |
| ▸ | CPA3 | P15088 | 1/20 | 0.56 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 6/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3960051 | 1.00 | CPA1 (0.56) | CPA1CPB1CPA3CPB2FOLH1 | |
| SCHEMBL3960054 | 1.00 | CPA1 (0.56) | CPA1CPB1CPA3CPB2FOLH1 | |
| SCHEMBL4609155 | 0.83 | POLB (0.41) | CPA1CPB1CPA3CPB2FOLH1 | |
| SCHEMBL3960108 | 0.83 | POLB (0.41) | CPA1CPB1CPA3CPB2FOLH1 | |
| SCHEMBL8817674 | 0.80 | TTR (0.48) | CPA1CPB1CPA3CPB2FOLH1 | |
| SCHEMBL3517307 | 0.79 | CPA1 (0.47) | CPA1CPB1CPA3CPB2FOLH1 | |
| SCHEMBL3517309 | 0.79 | CPA1 (0.47) | CPA1CPB1CPA3CPB2FOLH1 | |
| SCHEMBL2166740 | 0.77 | KDM6B (0.53) | FOLH1PTPN1TTRCYP2C9TSHR | |
| SCHEMBL2166747 | 0.77 | KDM6B (0.53) | FOLH1PTPN1TTRCYP2C9TSHR | |
| SCHEMBL4478582 | 0.76 | CPA1 (0.45) | CPA1CPB1CPA3CPB2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-20040214819-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2004-10-28 | — | — | US | disclosed |
| US-6344449-B1 | HEADACHE AND MORPHINE DEPENDENCE | DR. KARL THOMAE GMBH (DE) | 2002-02-05 | — | — | US | disclosed |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2001-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | CPA1 621/4885CPB1 1738/4885CPA3 986/4885 |
| US-20040214819-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | CPA1 511/4885CPB1 1459/4885CPA3 688/4885 |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | CPA1 511/4885CPB1 1459/4885CPA3 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.